The MDS Foundation proudly partners with the following organizations
The MDS Foundation proudly partners with the following organizations
Phone within the US
1-(800)-637-0839Outside the US only
1-(609)-298-1035Address
The MDS Foundation
228 Park Ave S
PMB 118983
New York
NY 10003-1502
The MDS Foundation is a global nonprofit 501(c)(3) advocacy organization (EIN 22-3283911), supporting patients, families, and healthcare providers in the fields of MDS and related diseases for over 30 years.
© 2024 MDS Foundation. All rights reserved.
Every gift helps patients, caregivers, and healthcare professionals access life-saving resources, support, and education. Together, we can make a difference. Even a small contribution can create a big impact. Thank you for your generosity.
Latest News
Explore the forefront of MDS research, treatments, and community happenings to stay informed on the ever-evolving landscape of MDS care.
May 22, 2025
Taiho Oncology Presents Data at the 2025 American Society of Clinical Oncology Annual Meeting
Taiho Oncology announced the presentation of data at the 2025 American Society of Clinical Oncology Annual Meeting. Highlights include a potential novel, all-oral therapy for AML.
May 19, 2025
Vor Bio to Explore Strategic Alternatives Following Clinical Program Wind-Down
Vor Bio has announced the initiation of a process to explore strategic alternatives—including a potential sale, merger, or asset licensing—amid a challenging funding environment. The company will wind down its clinical and manufacturing operations and has implemented a 95% workforce reduction while retaining a core team to support the strategic review.
May 14, 2025
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced the presentation of new data on the company’s PK activators, mitapivat and tebapivat, in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025.
April 28, 2025
Faron Announces Positive Phase II Results for Bexmarilimab in Higher-Risk Myelodysplastic Syndrome
Faron Pharmaceuticals has announced positive topline results from its Phase II BEXMAB trial in treatment-resistant higher-risk myelodysplastic syndrome (HR MDS). The combination of bexmarilimab and azacitidine showed high overall response rates and continued strong tolerability. Full data has been submitted to the 2025 ASCO Annual Meeting, and preparations for a Phase III trial are underway.
April 28, 2025
Taiho Oncology to Present New Data at 2025 ASCO Annual Meeting, Including Two Oral Presentations
Taiho Oncology will showcase findings from five studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including two oral presentations. Highlights include data on novel therapies such as an all-oral decitabine-cedazuridine combination for AML, zipalertinib for NSCLC with EGFR exon 20 insertion mutations, and real-world studies on metastatic colorectal cancer and cholangiocarcinoma treatments.
April 15, 2025
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML
A plain-language summary of the ASCERTAIN Phase 3 trial reveals that oral decitabine and cedazuridine (DEC-C) is as effective as intravenous decitabine for patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The study showed near-identical drug levels in the bloodstream, similar survival outcomes, and comparable side effects. With over half of transfusion-dependent patients achieving independence and the convenience of oral dosing, the findings support oral DEC-C as a practical alternative to IV treatment.
April 15, 2025
Orca Bio’s Orca-T Outperforms Standard Stem Cell Transplant in Phase 3 Trial for Blood Cancers
Orca Bio reports groundbreaking Phase 3 results from the Precision-T study, showing that its investigational therapy Orca-T significantly improves survival free of chronic graft-versus-host disease compared to traditional allogeneic stem cell transplants in patients with AML, ALL, MDS, and MPAL. The therapy demonstrated a 78% cGvHD-free survival rate at one year, with 94% overall survival. Findings will be presented at the 51st EBMT Annual Meeting and support Orca Bio’s upcoming FDA submission.
April 1, 2025
MDS Message Board Transitions to an Enhanced Platform – MDS Exchange
The MDS Foundation is excited to announce the transition of its MDS Message Board to a new and enhanced platform - MDS Exchange.
MDS Exchange is a safe space for patients and carers to connect with other members of the MDS community, share their story, and find disease-specific resources and support. This enhanced community provides a more user-friendly interface, new features for deeper engagement, and ensures that the MDS community can continue to connect, share, and support each other with even greater ease.
